Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma -: Results of a multicenter randomized prospective trial

被引:265
作者
Rhodes, LE
de Rie, M
Enström, Y
Groves, R
Morken, T
Goulden, V
Wong, GAE
Grob, JJ
Varma, S
Wolf, P
机构
[1] Univ Manchester, Hope Hosp, Dermatol Ctr, Photobiol Unit, Salford M6 8HD, Lancs, England
[2] Royal Liverpool Univ Hosp, Dept Dermatol, Liverpool, Merseyside, England
[3] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1105 AZ Amsterdam, Netherlands
[4] Norra Alvsborgs Lanssjukhus, Dept Dermatol, Trollhattan, Sweden
[5] UCL, Ctr Dermatol, London, England
[6] Haukeland Hosp, Dept Dermatol, N-5021 Bergen, Norway
[7] Leeds Gen Infirm, Dept Dermatol, Leeds, W Yorkshire, England
[8] Hop St Marguerite, Dept Dermatol, Marseille, France
[9] Univ Wales Hosp, Dept Dermatol, Cardiff CF4 4XW, S Glam, Wales
[10] Graz Univ, Dept Dermatol, Graz, Austria
关键词
D O I
10.1001/archderm.140.1.17
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Photodynamic therapy (PDT) is increasingly used as a noninvasive treatment for nodular basal cell carcinoma (BCC), without a sound evidence base. Objective: To compare topical PDT, with the use of the sensitizer methyl aminolevulinate, and standard excision surgery in nodular BCC. Design: Prospective, randomized study. Setting: University dermatology departments. Patients: A total of 101 adults with previously untreated nodular BCC. Interventions: Patients received methyl aminolevulinate PDT (n = 52) or surgery (n = 49). The PDT was given twice, 7 days apart, with methyl aminolevulinate cream (160 mg/g) and 75 J/cm(2) red light (570-670 nm). Thirteen patients with a noncomplete response to PDT at 3 months (24% lesions) were retreated. Outcome Measures: Primary end point was clinically assessed lesion clearance at 3 months after treatment. Secondary end points were sustained response rate at 12 months and cosmetic outcome at 3 and 12 months. Results: Data from 97 patients (105 lesions) were included in the 3-month per-protocol analysis. Complete response rates did not differ significantly between groups (51/52 [98%] lesions with surgery vs 48/53 [91%] lesions with methyl aminolevulinate PDT; difference [95% confidence interval], 4.8% (-3.4% to 13.0%1; P = .25). At 12 months, tumor-free rates were 50 (96%) of 52 lesions with surgery vs 44 (83%) of 53 with methyl aminolevulinate PDT (P = .15). More patients treated with methyl aminolevulinate PDT than surgery had an excellent or good cosmetic outcome at all time points (significant at 12 and 24 months on patient assessment, P < .05, and at 3, 12, and 24 months on investigator evaluation, P < .001). At 24 months, 5 lesions that had initially cleared with methyl aminolevulinate PDT had recurred, compared with I after surgery. Conclusions: Methyl aminolevulinate PDT is an effective treatment for nodular BCC, and while there is a trend for higher recurrence with this modality, it conveys the advantage over surgery of better cosmesis.
引用
收藏
页码:17 / 23
页数:7
相关论文
共 50 条
  • [21] Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolaevulinic acid 20% vs. two-stage topical methyl aminolaevulinate: results of a randomized controlled trial
    Kessels, J. P. H. M.
    Kreukels, H.
    Nelemans, P. J.
    Roozeboom, M. H.
    van Pelt, H.
    Mosterd, K.
    de Haas, E. R. M.
    Kelleners-Smeets, N. W. J.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (05) : 1056 - 1063
  • [22] Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial
    Choi, S. H.
    Kim, K. H.
    Song, K. H.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (05) : 783 - 788
  • [23] Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial
    Mosterd, K.
    Thissen, M. R. T. M.
    Nelemans, P.
    Kelleners-Smeets, N. W. J.
    Janssen, R. L. L. T.
    Broekhof, K. G. M. E.
    Neumann, H. A. M.
    Steijlen, P. M.
    Kuijpers, D. I. M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (04) : 864 - 870
  • [24] Topical photodynamic therapy with the iron chelator, CP94, for nodular basal cell carcinoma
    Morton, CA
    Campbell, S
    Gould, D
    Curnow, A
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P120 - P120
  • [25] A clinical investigation to determine the effect of pressure injection on the penetration of topical methyl aminolevulinate into nodular basal cell carcinoma of the skin
    Campbell, S. M.
    Pye, A.
    Horton, S.
    Matthew, J.
    Helliwell, P.
    Curnow, A.
    [J]. JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY, 2007, 26 (04) : 295 - 303
  • [26] Photodynamic Therapy Using Methyl Aminolevulinate in the Management of Primary Superficial Basal Cell Carcinoma: Clinical and Health Economic Outcomes
    Caekelbergh, Karin
    Nikkels, Arjen F.
    Leroy, Bernard
    Verhaeghe, Evelien
    Lamotte, Mark
    Rives, Vincent
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2009, 8 (11) : 992 - 996
  • [27] The cost-effectiveness of methyl aminolevulinate photodynamic therapy (MAL-PDT) for basal cell carcinoma
    Orme, ME
    Howard, P
    [J]. VALUE IN HEALTH, 2004, 7 (03) : 248 - 249
  • [28] Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma
    Vinciullo, C
    Elliott, T
    Francis, D
    Gebauer, K
    Spelman, L
    Nguyen, R
    Weightman, W
    Sheridan, A
    Reid, C
    Czarnecki, D
    Murrell, D
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (04) : 765 - 772
  • [29] Photodynamic therapy for nodular basal cell carcinoma in Korean patients
    Lee, Ki-Yeol
    Hong, Jin-Woo
    Lee, Chae-Young
    Kim, Ki-Ho
    Kim, Young-Hun
    [J]. JOURNAL OF DERMATOLOGY, 2010, 37 : 133 - 133
  • [30] Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial
    Roozeboom, M. H.
    Nelemans, P. J.
    Mosterd, K.
    Steijlen, P. M.
    Arits, A. H. M. M.
    Kelleners-Smeets, N. W. J.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (03) : 739 - 745